All Inquiries: 1+ 888-430-2221
OTCQB: CBBT   Cerebain Biotech Corp  

Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board


-Preeminent Neuropsychiatry Physician Joins Scientific Advisory Board of Alzheimer’s Disease R&D Company-

January 29, 2015 – Dallas, Tx., — Cerebain Biotech (CBBT) today announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.

Currently Dr. Husain is Professor of Psychiatry, Neurology & Medicine at Duke University Medical Center and member of Duke Institute for Brain Sciences.

“I am pleased to join the Scientific Advisory Board of Cerebain Biotech. The Company’s work, while early stage, offers a potentially new approach to the treatment of Alzheimer’s Disease, affecting 5.5 million people in the United States. Alzheimer’s is also the only top ten killer for which there are no effective treatment options available,” said Dr. Husain.

“We are extremely pleased to welcome Dr. Husain to our Scientific Advisory Board,” said Eric Clemons, president and CEO of Cerebain Biotech. “Dr. Husain’s expertise, experience and background will be invaluable as we navigate the path forward and try to develop a new and more effective treatment for Alzheimer’s Disease.”

About Cerebain Biotech Corp.

Cerebain Biotech (CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. These impacts were so compelling they led to the use of a highly invasive surgical procedure that successfully improved brain function in virtually all of the observed patients. The risks associated with the procedure, however, rendered it all but obsolete. The Company’s approach will consider both a medical device solution as well as a synthetic drug solution.

Forward-Looking Statements

This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Download Press Release